Vanguard Group’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-2,461,975
| Closed | -$11.9M | – | 4121 |
|
|
2020
Q1 | $11.9M | Buy |
2,461,975
+96,901
| +4% | +$628K | ﹤0.01% | 2533 |
|
|
2019
Q4 | $25.1M | Buy |
2,365,074
+137,029
| +6% | +$1.36M | ﹤0.01% | 2420 |
|
|
2019
Q3 | $23.2M | Buy |
2,228,045
+294,590
| +15% | +$3.85M | ﹤0.01% | 2416 |
|
|
2019
Q2 | $29.6M | Buy |
1,933,455
+237,768
| +14% | +$3.44M | ﹤0.01% | 2345 |
|
|
2019
Q1 | $21.8M | Buy |
1,695,687
+376,091
| +29% | +$4.25M | ﹤0.01% | 2469 |
|
|
2018
Q4 | $12.5M | Buy |
1,319,596
+41,567
| +3% | +$539K | ﹤0.01% | 2660 |
|
|
2018
Q3 | $21.2M | Buy |
1,278,029
+18,487
| +1% | +$296K | ﹤0.01% | 2549 |
|
|
2018
Q2 | $20.2M | Buy |
1,259,542
+148,043
| +13% | +$2.64M | ﹤0.01% | 2559 |
|
|
2018
Q1 | $17M | Buy |
1,111,499
+156,242
| +16% | +$2.44M | ﹤0.01% | 2565 |
|
|
2017
Q4 | $14.9M | Buy |
955,257
+74,638
| +8% | +$998K | ﹤0.01% | 2629 |
|
|
2017
Q3 | $9.78M | Buy |
880,619
+16,851
| +2% | +$158K | ﹤0.01% | 2817 |
|
|
2017
Q2 | $7.95M | Buy |
863,768
+38,615
| +5% | +$322K | ﹤0.01% | 2888 |
|
|
2017
Q1 | $7.05M | Buy |
825,153
+204,228
| +33% | +$1.86M | ﹤0.01% | 2919 |
|
|
2016
Q4 | $6.64M | Buy |
620,925
+26,248
| +4% | +$317K | ﹤0.01% | 2927 |
|
|
2016
Q3 | $6.44M | Buy |
594,677
+67,986
| +13% | +$553K | ﹤0.01% | 2880 |
|
|
2016
Q2 | $3.57M | Buy |
526,691
+19,877
| +4% | +$125K | ﹤0.01% | 3128 |
|
|
2016
Q1 | $2.36M | Buy |
506,814
+36,565
| +8% | +$179K | ﹤0.01% | 3315 |
|
|
2015
Q4 | $2.97M | Buy |
470,249
+11,913
| +3% | +$96.7K | ﹤0.01% | 3232 |
|
|
2015
Q3 | $4.05M | Buy |
458,336
+22,723
| +5% | +$238K | ﹤0.01% | 3066 |
|
|
2015
Q2 | $5.13M | Buy |
435,613
+6,659
| +2% | +$92.5K | ﹤0.01% | 3005 |
|
|
2015
Q1 | $6.21M | Buy |
428,954
+120,071
| +39% | +$1.84M | ﹤0.01% | 2883 |
|
|
2014
Q4 | $5.27M | Buy |
308,883
+8,453
| +3% | +$122K | ﹤0.01% | 2876 |
|
|
2014
Q3 | $3.74M | Buy |
300,430
+19,982
| +7% | +$246K | ﹤0.01% | 2990 |
|
|
2014
Q2 | $4.11M | Buy |
280,448
+3,310
| +1% | +$50.7K | ﹤0.01% | 2945 |
|
|
2014
Q1 | $5.64M | Buy |
277,138
+73,432
| +36% | +$1.78M | ﹤0.01% | 2759 |
|
|
2013
Q4 | $3.99M | Buy |
203,706
+29,350
| +17% | +$783K | ﹤0.01% | 2912 |
|
|
2013
Q3 | $7.9M | Buy |
174,356
+18,863
| +12% | +$615K | ﹤0.01% | 2511 |
|
|
2013
Q2 | $3.71M | Buy |
+155,493
| New | +$2.48M | ﹤0.01% | 2826 |
|
Vanguard Group's STML Position: Q2 2020 in Review
Vanguard Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 2,461,975 shares — an estimated $11.9M sold.
Vanguard Group first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $29.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Vanguard Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Vanguard Group sold 2,461,975 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $11.9M.
- Vanguard Group first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Vanguard Group's Stemline Therapeutics, Inc. position peaked at $29.6M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Vanguard Group's 13F filing for Q2 2020, filed 14 Aug 2020.